Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Staskin

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Advances in Therapy|December 18, 2021
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWURJeffrey Frankel, David Staskin, Susann Varano, et al.
Neurourology and Urodynamics|July 14, 2017
Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patientsDudley Robinson, Con Kelleher, David Staskin, et al.
The Journal of Urology|March 20, 2020
Reply by AuthorsSteven A Kaplan, Sender Herschorn, Kevin T McVary, et al.
The Journal of Urology|January 3, 2020
Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS)Steven A Kaplan, Sender Herschorn, Kevin T McVary, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Advances in Therapy|December 18, 2021
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWURJeffrey Frankel, David Staskin, Susann Varano, et al.
Neurourology and Urodynamics|July 14, 2017
Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patientsDudley Robinson, Con Kelleher, David Staskin, et al.
The Journal of Urology|March 20, 2020
Reply by AuthorsSteven A Kaplan, Sender Herschorn, Kevin T McVary, et al.
The Journal of Urology|January 3, 2020
Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS)Steven A Kaplan, Sender Herschorn, Kevin T McVary, et al.
Pageof 6